SCHEMBL4881285

SCHEMBL4881285

O=C(O)c1cn(-c2ccc(F)cc2)c(I)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 2/20 0.45
GABRB2 P47870 2/20 0.45
KDM4E B2RXH2 3/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
ATM Q13315 1/20 0.40
PPP1CA P62136 1/20 0.38
NOTUM Q6P988 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
CNR1 P21554 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
BCL2L1 Q07817 1/20 0.35
BAD Q92934 1/20 0.35
P4HTM Q9NXG6 1/20 0.35
ABCB1 P08183 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27609617 0.73 CNR1 (0.65) GABRA2GABRB2KMT2APTGS2CNR1
SCHEMBL4887399 0.72 MEN1 (0.45) GABRA2GABRB2KMT2AMEN1ATM
SCHEMBL6840264 0.69 KCNH2 (0.40) GABRA2GABRB2KDM4ELMNAKMT2A
SCHEMBL5781140 0.69 GABRA2 (0.55) GABRA2GABRB2LMNAPTGS1PTGS2
SCHEMBL5169774 0.69 KMT2A (0.45) GABRA2GABRB2KMT2AMEN1ATM
SCHEMBL5169770 0.69 ALDH1A1 (0.46) KDM4EKMT2AMEN1ATMP4HTM
SCHEMBL2330243 0.68 CA1 (0.57) KMT2ANOTUMPTGS1PTGS2
SCHEMBL2174602 0.68 KDM4E (0.48) KDM4EKMT2AMEN1
SCHEMBL870792 0.67 PTGS1 (0.59) PTGS1PTGS2
SCHEMBL27911606 0.67 CA1 (0.56) KMT2ANOTUMPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481548-B2 2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-4-trifluoromethyl-pyrimidine; metabotropic glutamate (mGluR5) receptor antagonist; analgesic, neurodegenerative diseases; psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognititve disorders, memory deficits, chronic and acute pain HOFFMAN-LA ROCHE INC. (US) 2013-07-09 US disclosed
US-20080119489-A1 IMIDAZOLE DERIVATIVES BUETTELMANN BERND 2008-05-22 US disclosed
US-20080103306-A1 IMIDAZOLE DERIVATIVES BUETTELMANN BERND 2008-05-01 US disclosed
US-7332510-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119489-A1 IMIDAZOLE DERIVATIVES GRIK5, GRM5, GRIN2B GABRA2 85/4885GABRB2 166/4885KDM4E 1410/4885
US-20080103306-A1 IMIDAZOLE DERIVATIVES GRIK5, GRM5, GRIN2B GABRA2 78/4885GABRB2 139/4885KDM4E 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.